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ABSTRACT OF THE THESIS

AN APPROACH FOR CLARIFICATION OF THE MECHANISM OF
INACTIVATION OF RIBONUCLEOTIDE REDUCTASES WITH
3'["0]-LABELED 2'-AZIDO-2'-DEOXYNUCLEOTIDES
by
Saiful Mahmud Chowdhury
Florida International University, 2001
Miami, Florida
Professor Stanislaw F. Wnuk, Major Professor

Inactivation of ribonucleotide reductases

by 2'-azido-2'-deoxynucleotides

is

accompanied by appearance of new EPR signals for a nitrogen-centered radical. The
structure of this elusive nitrogen-centered radical has been studied extensively and shown
to be derived from azide moiety. Synthesis of 3'[

7

0]-labeled

2'-azido-2'-deoxyuridine-5'-

diphosphate was targeted in this research. Such a labeled analogue should perturb the
EPR spectrum in predictable fashion, and the hyperfine interaction between the free
electron and the 17

nucleus should allow the choice between the recently proposed

structures of this elusive radical (Van Der Donk, W. A. et al. J Am. Chem. Soc. 1995,

117, 8908-8916).

The labeled 2'-azido-2'-deoxynucleotides was prepared by thermolysis of 02,3'anhydrouridine

to

give

the

more

stable

2

,2'-anhydrouridine

derivatives

with

concomitant rearrangement of the 2'-O-benzoyl[1 70] group into the 3'-[ 1 7 0]-benzoyl

V

intermediate. Deprotection and ring opening with LiF/Me 3SiN3 gave the 3'[

7

0]-2--azido

2'-deoxyuridine. Tosylation (05') and displacement of the 5'-tosylate by treatment with
tris(tetra-n-butylarmonium)

hydrogen

pyrophosphate

gave

3'[ 17 O]-2'-azido-2'-

deoxyuridine 5'-diphosphate. All the intermediates and the products were characterized
by 'H-NMR,

13

C-NMR,

3

IP-NMR

and isotopic enhancement was confirmed by using

mass spectrometry.
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1. INTRODUCTION

1.1 GENERAL INTRODUCTION
One of the major scientific achievements of the twentieth century has been the
identification, at the molecular level, of the chemical interactions that are involved in the
transfer of genetic information and the control of protein biosynthesis. The substances
involved are biological macromolecules called nucleic acids. The history of the
determination of the structure and function of nucleic acids began in 1868 when F.
Miesher

l

isolated a material rich in phosphorus from the nuclei of pus cells and from the

sperm of a salmon. Miesher later found that this material is a common constituent of
yeast, kidney liver, testicular, and nucleated red blood cells. He named this

material

nuclein. It was later named nucleic acid by Altmann.
The two major types of nucleic acids are named ribonucleic acid (RNA) and
deoxyribonucleic acid (DNA). DNA and some RNA are very large polymeric molecules
of high molecular weight, which preserve hereditary information that is transcribed and
translated in a way that allows the synthesis of all of the various proteins in the cell. The
genetic message is transcribed from DNA onto a form of RNA called messenger RNA
(mRNA). This messenger RNA acts as a template for protein synthesis.

4

Nucleic acids are long, thread-like polymers made up of a linear array of

monomers

called nucleotides. Different nucleic acids can have from around 80

nucleotides, as in transfer RNA, to over 108 nucleotide pairs as in a single eukaryotic
chromosome. 5 The unit size of a nucleic acid is called a base pair (for double-stranded

1

species) and a base (for single-stranded species). The genomic DNA of a single human
cell has 3900 Mbp (million base pairs) and is 990 m long.
Mild degradation of nucleic acids yields their monomeric units, a mixture of
phosphate esters called nucleotides. These are components of both ribonucleic acid
(RNA) and deoxyribonucleic acid (DNA). RNA is made up of ribonucleotides while the
monomers of DNA are called 2'-deoxyribonucleotides. Removal of the phosphate group
from nucleotides converts them into compounds known as nucleosides.

All nucleotides are constructed from three components: a nitrogen heterocyclic
base, a pentose sugar, and a phosphate residue. The major bases are monocyclic
pyrimidines or bicyclic purines. The major bases obtained from DNA are the purines,
adenine (A) 1 and guanine (G) 2, and the pyrimidines cytosine (C) 3, thymine (T) 4.
RNA bases are mainly adenine, guanine, cytosine, and another pyrimidine base, uracil

(U) 5 (Figure 1). In nucleosides and nucleotides, the purine or pyrimidine base is joined
from the ring nitrogen to carbon-I of a pentose sugar. The nucleosides, which are found
in RNA are named adenosine 6, guanosine 7, cytidine 8, and uridine 10. In ribonucleic
acid (RNA), the pentose is D-ribose which is locked into a five membered furanose ring
by a bond from C-1 of the sugar to N-1 of C or U or to N-9 of A or G. In DNA, the
pentose is 2-deoxy-D-ribose and the four nucleosides are 2'-deoxyadenosine 11, 2'deoxyguanosine 12, 2'-deoxycytidine 13, and 2'-deoxythymidine 9.
The phosphate esters of nucleosides are called nucleotides, and the simplest of
them have one of the hydroxyl groups of the pentose esterified by a single phosphate
monoester function. Adenosine 5'-phosphate 14 is a 5'-ribonucleotide and is also called

adenylic acid (Figure 2). Similarly, 2'-deoxycytidine 3'-phosphate 15 is a 3'-deoxy
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Figure 1: Different types of

3

nucleosides

Y

nucleotide. Nucleotides with two phosphate monoesters on the same sugar are called

nucleoside biphosphates (e.g., 16) and a nucleoside monoester of pyrophosphoric acid is
called nucleoside diphosphate 17.
The primary structure of DNA has a string of nucleosides, each joined to its two
neighbors through phosphodiester linkages. Each regular 5'-hydroxyl group is linked
through a phosphate to a 3'-hydroxyl group. The uniqueness of any primary structure
depends only on the sequence of bases in the chain. The secondary structure of DNA
was proposed by Watson and Crick 6 in 1953. They proposed a double helix as a model
for the secondary structure of DNA. According to this model, two nucleic acid chains are
held together by hydrogen bonds between base pairs on opposite strands (e.g., T=A;
C-G). Protein biosynthesis is directed by DNA through the agency of several types of
ribonucleic acids called messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal
RNA (rRNA). The two main stages in protein biosynthesis are transcription and
translation.

In the transcription stage, a molecule of mRNA, having a nucleotide

sequence complementary to one of the strands of DNA double helix, is constructed. In
the translation stage, triplets of nucleotides of mRNA, called codons are recognized by
the complementary anticodon base sequences of transfer RNA (tRNA) for a particular
amino acid, and that amino acid is added to the growing peptide chain.

7

Since nucleosides are the fundamental building blocks of DNA and RNA,
nucleoside analogues have been synthesized as anticancer and antiviral chemotherapeutic
agents. These nucleoside analogues have chemical structures slightly different from those
of natural nucleosides. If the "foreign" nucleoside is incorporated into the nucleic acid of
a cancer cell, it could interfere with the cell

metabolism

4

and be fatal to the cell. Viral
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nucleic acids can be modified in the same way. This antimetabolite approach has

stimulated a search for new types of this class of compounds. The second approach is the
design of highly specific, low toxicity drugs that act as mechanism-based enzyme
inhibitors. Mechanism-based enzyme inhibitors are chemically unreactive compounds,
and this is the key feature that makes the drug so amenable to drug design.8 Because of
their lack of reactivity, nonspecific modifications of other proteins are generally not a
problem. Ideally, one target enzyme will be capable of catalyzing the appropriate reaction
that converts the mechanism-based inactivator into its reactive form, and it also will have
an appropriately juxtaposed nucleophile that can react with the incipient electrophilic
center.5

1.2 RIBONUCLEOTIDE REDUCTASES
Ribonucleotide reductases (RNRs) are enzymes that execute the 2'-deoxygenation
of ribonucleotide 5'-di-and triphosphate in unique de novo biosynthesis pathways to form
DNA monomers 91' 0 (Scheme I). There are several types of ribonucleotide reductases;
they are classified according to their cofactor requirements."1
The

RNR isolated

from bacteria grown under aerobic conditions is prototypical of

the Class I RNRs, which also include mammalian and herpes simplex virus (HSV) RNRs.
This enzyme uses ribonucleotide diphosphate (RDPR) as the substrate. It is composed of
two homodimeric subunits, R1 and R2. The R2 subunit contains a cofactor, which is
composed of an unusual pt-oxo-bridged diferric cluster adjacent to a tyrosyl radical (.Tyr
122 in Escherichia coli). The tyrosyl radical is essential for catalysis and is generated by
the diferrous form of R2 in the presence of molecular oxygen.

6

The RNR isolated from Lactobacillus leichimannii (class 11) requires adenosyl

cobalamin (Adocbl = coenzyre B12) as a radical generated cofactor. These enzymes use
ribonucleotide triphosphate (RTPR) as substrate. RTPR is a single polypeptide (M, = 76
kda), which catalyzes the conversion of nucleotide triphosphates (NTPs) to 2'deoxynucleotide triphosphate (dNTPs) with concomitant oxidation of two active sites of
thiols to disulfides.
The

RNR

isolated from

E.

coli grown under anaerobic conditions (class III) is

distinct from the enzyme produced under aerobic conditions (class I). When isolated, it is
proved to have an essential glycyl radical, which is generated by the second subunit of
the enzyme that is equivalent to R2 in the aerobic

E.

coli RNR. The activating enzyme

requires S-adenosylmethionine and an iron-sulfur cluster to generate the glycyl radical
via a novel mechanism.
The RNR from Brevibacteriumi an;moniagenes (which is considered as class IV)
has been recently characterized. It is thought to possess an u 2 p subunit structure and a
dinuclear Mn3 cluster analogous to the diferric cluster of aerobic

E.coli RNR.

This class

of enzymes is poorly understood.
Despite the dramatic

differences in these reductases (Figure

3),"

their

mechanisms unusual, involving exquisitely controlled radical base chemistry. Each of
the metallo-cofactors initiates these radical-dependent nucleotide reduction processes by
generating a transient protein radical. The working
characterized RNRs, those from
tyrosyl radical (in

E.

generate thiyl radical.'

E.

model

is based on the two best

coli and L. leichinannii. The function of both the

coli) and the adenosylcobalamin radical (in L. leichmannii) is to
2

0

0
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Work in this dissertation was correlated with the mechanism of the ribonucleoside

diphosphate reductase (RDPR) of

E.

coli since it closely resembles the

mammalian

ribonucleotide reductases. The diferric-tyrosyl radical required by class I RNR are
potentially attractive targets for the design of antitumor and antiviral agents.

The

reminder of this introduction will focus on the structure, mechanism and inhibition of

RDPR.

1.2.1 STRUCTURE OF RDPR
Structural studies and sequence alignments, in conjunction with chemical and
biochemical studies, have provided us with a generic picture of class I RDPR (Figure
4) .913 The structure of these enzyres has been extensively studied and characterized by
Thelander and Reichard.

The ribonucleoside diphosphate reductase from Escherichia

coli has two nonidentical subunits. They are known as proteins RI and R2 and exist in a

1:1 complex with the active site proposed to be at the interface of these subunits. Protein
RI is a dimer (cL') and has a molecular weight of 160,000. The functional end of the
molecule is the Rl subunit. It contains the binding sites for the purine and pyridimine
diphosphate substrates and for the dNTPs and ATP, which act as allosteric effectors. In
addition, it contains the five cysteines that are essential for catalysis. Cysteines 225 and
462 are oxidized to the disulfide during nucleotide reduction, thus providing the required
reducing equivalents. Cys754 and Cys759 are at the carboxy-terminal trail of RI and are
not detectable in the X-ray structure due to thernal flexibility. They shuttle reducing
equivalents into and out of the active sites va disulfide interchange with thioredoxin

sa
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Tordo Geei

SH
SF SH10F
SSH
s7
Schr 4 eneri I:RpRctredufctioassytRNR

NAL)P FADW

R20

Rpbcctured ofedlastIase

dD

Scheme II). The fifth cysteine (Cys439) is proposed to initiate nucleotide reduction by
3'-hydrogen atom abstraction.
The protein R2 consists of two apparently-identical polypeptide chains (P2) and
has a molecular weight of 78,000. The R2 subunit contains the diferric iron center and
the tyrosyl radical essential for the reduction process.16' 17

The EPR spectrum of the

tyrosyl radical shows a doublet ( = 2.0047), with super imposed hyperfine interaction.
The UV-VIS spectrum possesses a sharp absorption at 410 nm ( = 3250 M-cn1). This
cofactor is buried in R2, lying 10A from the nearest surface. It has been proposed that
the tyrosyl radical generates the thiyl radical on Cys439 of R1 by long-range electron
transfer, which is some 35

A

away, thus initiating the nucleotide reduction processes.

The mechanism of communication between these subunits is a major focus of
investigation.

1.2.2 MECHANISM OF ACTION OF RDPR
Biochemical and chemical model studies have allowed one to formulate a
chemically reasonable hypothesis for the reduction reaction catalyzed by RDPR.

The

first proposal for a generic nucleotide reduction which involves a radical mechanism was
proposed by Stubbe and coworkers (Scheme III).19
The first steps in this mechanism involve a protein-mediated hydrogen atom
abstraction from the 3'-carbon of NDP to produce a 3'-nucleotide radical. In the second
step, protonation of 2'-OH can be achieved by proton transfer from the active dithiols in
the R1 subunit. This would facilitate the cleavage of the C2'-OH bond and result in
formation of a radical cation. After loss of water, the two cysteines on the c face of the

11

nucleotides (Cys462, Cys225) deliver the required reducing equivalents, generating a 3'radical 2'-deoxynucleotide intermediate. This intermediate is subsequently reduced to
give dNDP and a disulfide with regeneration of the radical initiator for the next turnover
of the enzyme.

Two important features of this mechanism are: (1)

abstraction of the H3' atom

which is necessary for the cleavage of the C2'-OH bond; (2) the hydrogen, which is
abstracted from the 3' position in the starting materials, is returned to the 3' position in the
products.
These two predictions have been experimentally established. The first prediction
is that C3'-H bond of the NDP substrate is cleaved.
measurement of isotope effects where N is either p

Use of [3'- 3 H] NDPs and

midine or purine and with the

presence of differing allosteric effectors have unambiguously established that RDPR is
capable of catalyzing cleavage of the C3'-H bonds. Control experiments using [1'-H] and
[2'- 3H] NDPs indicate no observable selection effects on RDPR- catalyzed reductions. In
addition, reduction of [3'-2H] UDPs by RDPR shows positive isotopic effects in support
of C3'-H cleavage. The second predictions, that hydrogen abstracted from the 3' position
in the starting materials is returned to the 3' position in the dNDP products, were verified
by the use of [3'-H] UDP and by analysis of the end-product by NMR.
The main feature of the proposed mechanism is the involvement of a radical
intermediate. Experimental efforts to ascertain its intermediacy utilized stopped- flow
techniques as well as the premise that Xe (protein radical) is tyrosyl radical 122.
Although the mechanism suggests the feasibility of a radical cation intermediate, no
direct evidence for this intermediate exists, and model studies indicated that at least one

12
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other option must be considered. Such an alternative might involve radical anion
intermediate in the mechanism.

At present, experimental results cannot distinguish

between a radical anion and radical cation mechanism.
Siegbahn's2

9

very recent theoretical analysis of the substrate reaction cascade

correlated mechanistic processes with amino acid residues identified in X-ray crystal
structure of the subunits. This elegant theoretical analysis preserves the fundamental
concept of the Stubbe mechanism and corrects the postulated cation radical character at
C2', and it offers for the first time a chemically and theoretically plausible route for the
overall rate limiting reduction of the 2'-deoxy-3'-ketone intermediate. Lenz and Giese
performed photochemical studies with selenoester models that fragment to generate
nucleoside mimics of the natural nucleoside with C3' radical.

1

Another recent study with

'-O-nitro ester nucleosides and 6'-0-nitro ester of homonucleosides was in harmony with
the Stubbe/Siegbahn mechanism for the reduction of substrate. This study provided a
biomimetic model for the free radical-induced relay reaction cascades postulated to occur
at the active sites of ribonucleotide reductases.2' 23

1.2.3 INHIBITION OF RDPR
The essential metallo-cofactor, the interactions between the two subunits of the
class I RNRs, and the unusual radical intermediate in the nucleotide reduction process
have all provided proven targets for the design of inhibitors of this essential enzyme.

Three potentially

complementary approaches have successfully targeted RNRs in

vitro based on the detailed understanding of the biochemistry of this system and of

nucleotide metabolism. One involves nucleotide analogs as mechanism-based inhibitors.

14

A second involves the reduction of tyrosyl radical required for initiation of nucleotide
reduction. The third focuses on the inhibition of the interaction of R1 and R2 subunits,
both of which are required for nucleotide reduction.
In 1976, Thelander and co-workers reported that 2'-chloro-2'-deoxynucleotides
such as C1CDP (X = Cl, Scheme IV) and 2'-azido-2'-deoxunucleotides (X = N 3 , Scheme
IV) such as N 3UDP or N 3 CDP are potent inactivators of RDPR.24 A detailed
understanding of the mechanism by which these compounds inactivate the enzyme has
evolved since their discovery.)
A generalized view of the mechanism responsible for enzyme inactivation by
nucleotide analogs is shown in Scheme IV." The initial steps, as in the case of NDP
reduction, is 3'-hydrogen atom abstraction by a thiyl radical at Cys439. Deprotonation of
3'-OH concomitant with removal of leaving group X results in the formation of a 2'-

deoxy-3'-ketonucleotide radical which can then be reduced from the top face (P-face) or
the bottom face (c-face) of the inhibitor. Reduction from the bottom face by dithiols
results ultimately in the inability to regenerate the thiyl radical on Cys439 and hence in
the case of F. coli RNR, the tyrosyl radical cannot be reformed. Since tyrosyl radical is
essential for catalysis, inactivation of R2 is a major mechanism of RNR inhibition by
many nucleotide mechanism based inhibitors.
Reduction from the

p-face

by Cys439 results also in the formation 3'-keto-2'-

deoxynucleotides which dissociate from the active sites and decompose to yield the 2methylene-3(2H)-furanone, which nonspecifically alkylates the R1 subunit of the
enzyme, thus inactivating it. The factors that determine whether the reduction occurs
from the top face or from the bottom face are not completely understood.

15

PP

S
*

5H

B

sa

POB

POB

H

Ha

SH SH

CO 2
441

462

CO2

SH

SH

-CO

s

8

S
H

SH

Reduction fromn top face

s2PPO

2

HSH

225

Reduction from bottomn face

-C0

2

H
I

H
~

PPO

4

B HPPO

B H

H
-CQ 2

ihssociation from protein

SH SR

loss of tyrosyl radical

Ppi
base

/

-

~

RI alkylation

Scheme IV: A generalized view of mechanism of inhibition of RDPR by
nucleotide analog

16

1.2.4

PROPOSED MECHANISM OF INHIBITION OF RDPR BY 2'-AZIDO-2'-

DEOXYURIDINE 5'-DIPHOSPHATE
In 1976,

Thelander, et al. reported

that 2'-azido-2'-deoxynucleosides

5'-

diphosphate (B = uracil or cytosine; Scheme V) are potent inactivators of E. coli
RDPR. 24 Several other studies with these inhibitors have provided much information
about the catalytic capabilities of this essential enzyme. 253 Thelander, et al. reported that
inactivation of RDPR by 2'-azido-2'-deoxycytidine

5'-diphosphate

(N 3CDP) was

accompanied by destruction of catalytically essential tyrosyl 122 radical Ye.2 4 In 1983,
Sjoberg, et al. found that inactivation of RDPR by 2'-azido-2'-deoxynucleotides was
accompanied by appearance of new EPR signals for a nitrogen-centered radical and
concomitant decay of the peaks for tyrosyl radical (Ye). 2 5 This nitrogen-centered radical
has been characterized by EPR spectroscopy and shown to be composed of a 1:1:1
anisotropic triplet arising from interaction with a single nitrogen (AN = 25G) and second
hyperfine interaction doublet possibly derived from a proton (AM = 6.3G).2

6

Isotopic

labeling of the R2 subunit of RDPR with 15N and 2 H caused no alteration of hyperfine
interaction with the new nitrogen-centered radical. This result leads to the hypothesis that
the new radical was derived from N 3CDP.25
Stubbe and co-workers presented the first conclusive evidence that the new
radical is derived from azide, since altered splitting of the EPR signal (triplet collapsed to
a doublet) was observed upon inactivation of RDPR with 2'-[15 N] N 3UDP. The
observation of a substrate-derived radical provided the first direct evidence for free
radical chemistry with RDPR.2 6

17

To understand the complex reaction catalyzed by RDPR, specific isotopically
labeled N 3 UDPs were prepared and incubated with RDPR, and the products and their
stoichiometries were ascertained. It was found that one equivalent of N 3UDP inactivated

one equivalent of RDPR.

This inactivation was accompanied by cleavage of the 3'

carbon-hydrogen bond (C3'-H) and production of one equivalent each of uracil, inorganic
pyrophosphate, and molecular nitrogen was observed. No N3~ was detected. Incubation
of [5'- 3H] N 3UDP with the protein resulted in covalent modification of the Ri

subunit

with one equivalent of label, accompanied by a change in absorption of the protein at 320
nm.7

These results, in conjunction with EPR studies, allowed the formulation of a
model (Scheme V)2 proposed by Salowe, et al. in 1987. These studies, however, were
unsuccessful in resolving some the aspects of the mechanism. The identity of the spin

!2

nucleus responsible for the observed 6.5 G doublet hyperfine interaction with the
nitrogen-centered radical (N.) has remained a mystery but is crucial to defining the
structure of the No. Deuterium labeling experiments, with [ 2H]-labeled R2 and with
N 3UDP ([ 2H]- labeled at the 1', 2', 3', 4' positions) have failed to reveal the source of
protein hyperfine interaction.25, 2 6,28

Doubly-labeled 2'[ 5 N3 ]- azido-2'-[' 3 C]-UDP was

prepared and incubated with RDPR.28 The reaction product was analyzed by EPR and
electron spin echo envelope modulation (ESEEM) spectroscopy. It was found that the
spectrum of the resulting nitrogen-centered radical has no hyperfine interaction with the
C13 nucleus, which requires cleavage of C2'-nitrogen bond.
Based on this experimental data, a new mechanism of inactivation was formulated
(Scheme VI). 2 8 The inactivation process is assumed to be initiated by 3' carbon-hydrogen
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of

RNR by

N3UDP

bond cleavage, evidenced by 'H20 release from [3' -3H] N 3UDP and is accompanied by
rapid loss of 1 equiv. of N 2 . Decay of the nitrogen-centered radical was accompanied by
complete destruction

of N 3UDP resulting

in the

formation

of uracil,

inorganic

pyrophosphate, and 2-methyl-3(2H)-furanone.
In addition, studies with a Cys225

Serine R1 mutant revealed no tyrosyl radical

loss or nitrogen-centered radical formation, but azide ion was observed (with mutant
Cys462+Ser the regular nitrogen-centered radical was detected). These results support
the mechanism outlined in Scheme VI and implicates Cys225 as a key player in the
conversion of azide to nitrogen and a nitrogen-centered radical.30
Furthermore, studies with a [p_-2H]-cysteine labeled R1 subunit have indicated
that the 6.5 G proton hyperfine interaction observed results from a P-hydrogen from of
Cys225 in R1. A novel structure was proposed by Vander Donk, et al. in which an initial
nitrogen-centered radical HN'Sys2 2 5 R1, not detected experimentally, reacts further with
the 3'-keto-2'-deoxynucleotides 5'-diphosphate (3-ketodUDP) to produce a new sequence
of events that generates the structures A or B (Scheme V).3

0

EPR and site-directed mutagenesis studies as well as published EPR results of the
model compounds have led to the conclusion that the nitrogen-centered radical must have
the structure XN'Sys225R1 in which X is an oxygen or carbon atom having no hydrogen
attached or a carbon atom with a single hydrogen attached but oriented in a defined
fashion. Vander Donk, et al. postulated that XN'Seys 2 2 5 R1 radical is sitting on the c face
of the carbonyl group of the 3'-ketoUDP and that it can interact with the carbonyl of this
ketone to generate either compound A or compound B (Scheme VII).

Molecular

modeling studies indicate that the distance between the 2'-proton and nitrogen in structure
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Donk, et al.?0
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A must be < 5A.

Electron spin echo envelope modulation

(ESEEM) spectroscopy

confirmed that structure A, while chemically appealing, is not a viable candidate for
nitrogen-based radical. Vander Donk, et al. proposed that structure B, which explains all
of the spectroscopic data, is the probable candidate for this elusive nitrogen-centered
radical.30

1.3 OBJECTIVE OF THE RESEARCH
In order to probe the above hypothesis, 30 synthesis of 3'[
deox

ridine 5'-diphosphate is targeted in this study.

7

O]-labeled 2'-azido-2'-

Such a labeled analog should

perturb the EPR spectrum of the nitrogen-centered radical in a predictable fashion, and
the hyperfine interaction between the free electron and the 17

nucleus should allow a

choice between the recently proposed structures of Vander Donk, et al. (Scheme VII).30
The proposed nitrogen-centered radical B would have a one bond hyperfine interaction
between 3'['0] and nitrogen while radical A would have a two bond interaction with the
3'["0] , which also has a 10- H interaction.

2. SYNTHESIS OF THE LABELED NUCLEOSIDES
Specific isotopically labeled compounds are of great importance in studying the
biochemistry and the metabolism of both naturally-occurring and synthetic nucleosides of
clinical importance. A literature survey indicates that there is a lack of a general
procedure for the incorporation of stable isotopes in nucleic acid components. Although
synthetic methods describing the incorporation of 18-oxygen and deuterium labeled into
the heterocyclic portion of nucleosides have been reported, procedures for labeling the

23

sugar

moiety

have been limited.',

2

Anhydronucleosides have been shown to be

versatile intermediates for the synthesis and the interconversion of pyrimidine
nucleosides.

Unfortunately,

most

ring

opening

reactions

of anhydropyrimidine

nucleosides result in the formation of pentofuranosides possessing the arabino or xylo

configuration rather then the desired ribo isomer. 3
The first general approach for the synthesis of specifically-labeled pyrimidine
nucleosides was reported by Schram, et al.34 A facile method for the synthesis of highly
enriched

8 0-labeled

pyridimine ribonucleotide was described using uridine as the

precursor. The isotopic label was selectively incorporated into 02 of the uracil moiety
and ribo portion of the molecule at the 5'-position. This methodology is outlined in
Scheme VIII.34
Basic hydrolysis of the 0 2 ,5'-anhydro bridge in 18 with Na' 8OH proceeds by
nucleophilic attack specifically at the C2 position of the heterocyclic base to afford 19
which was then deprotected to give 20.34 Reformation of the 0 2 ,5'-anhydro bridge by
reaction of 19 with triphenylphosphine and diethyl azodicarboxylate (DEAD) provided
the key intermediate compound 21. Treatment of 21 with unlabeled NaOH resulted in
cleavage of the anhydro linkage with the 180-label attached directly to the 5'-position to
give 22. Deprotection of 22 yielded 5'[18 0]-uridine 23. Alternatively, the 2,5'-anhydro
bond was cleaved with Na' 8 OH with the resultant incorporation of a second 180 atom
8
2
(structure 24) which, after removal of isopropylidene group, afforded the di-0 ,5'[" 0]-

labeled uridine 25.
The nonstereoselective synthesis of 3'[18O] uridine was reported by McCloskey, et
al. using the

moderately unstable

3'-keto derivative 27 as the critical intermediate
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5

Thus, 2',5'-di-O-trityluridine 26 was oxidized with CrO 3/Ac 20/pyridine

to give 3'-ketouridine derivative 27. Ketone 27 was treated with HClH

18
2

O to afford

2',5'-di-0-trityl-3'["0]-labeled 3'-ketouridine 29 through exchange 180 to 160 via hydrate
formation (28). Reduction of the ketone with NaBH 4 and detritylation followed by
tedious purification and isolation gave 3'[18 0]-ribo isomer 31 as the minor product and
undesired 3'[

18

0]-xylo isomer 30 as a major product (major to minor ratio 3:1).

3. RESULTS AND DISCUSSION
3.1 DESIGNING THE SYNTHESIS OF 3'-OXYGEN LABELED

COMPOUNDS

A literature search revealed that the only method available for the synthesis of 3'oxygen-labeled nucleosides involves oxidation of the 3'-OH function to 3'-keto
derivatives (e.g., 27).3$ The 3'-keto derivatives are then equilibrated with 18-oxygen
labeled H 2 0 under acidic conditions to give

18

0-labeled 3'-ketone (e.g., 29). Subsequent

reduction with NaBH 4 affords the 3'-oxygen labeled nucleoside derivatives as epimers of
xylo 30 and ribo 31 derivatives (Scheme IX). 5

Disadvantages of such an approach include:
a) Unfavorable reduction of 3'-ketone which, due to steric hindrance, gives the
undesired xylo epimer 30 as the major product (xylo/ribo 3:1).
b) Introduction of costly

7 0-labeled

material into the ribose moiety in the early

stage of synthesis of the targeted 2'-azido-2'-deoxyuridine inhibitor.
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c)

Equilibrium of 3 ' -ketone with "8

and

170

labeled water will give replacement of

unlabeled oxygen by labeled oxygen only with about 80% enrichment as reported
by McCloskey.
The disadvantages associated with the ketone approach for the synthesis of oxygenlabeled nucleosides prompted us to explore new methods for the selective labeling of the
sugar moiety. We designed a synthesis of 3'-[17] labeled 2'-azido-2'-deoxyuridine based
on the rearrangement3 6 of the 2'-O-benzoyl precursor into a

'-O-benzoyl product with

the concomitant formation of 02 2-anhydro ring from 0 2,3'-anhydro ring (vide infra
Scheme XIII).
The feasibility of this novel approach was first tested by using unlabeled
precursors. In the second phase of this investigation, 180-labeled precursors were
prepared from H2 1 0 in order to determine the stereospecificity and efficiency of
labeling. In the third phase, costly 17 0-labeled H 2 0 was used [18-oxygen H 2 0 is ~100
times cheaper than 17-oxygen labeled H 2 0 (5 g of H2 180 with 95% 180-enrichment costs
$100 whereas 1 g of H 2 17 0, with 74.5% 170 enrichment costs $2000)].

3.2 STEREOSELECTIVE INTRODUCTION OF THE LABELED OXYGEN AT
THE 3'-POSITION VIA FOX REARRANGEMENT
3.2.1

SYNTHESIS OF 02, 3'-ANHYDROURIDINE
Treatment of uridine 32 with three equivalents of triphenylmethyl chloride (TrCl)

gave 2',5'-di-0-trityluridine 33 as the only crystalline product in 45% yield as reported
by Fox. 36 This reaction was repeated several times at various scales from (2 g tol5 g),
and no attempts were made to increase the yield by purification of the mother liquors by
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column chromatography. Treatment of 33 with methanesulfonyl chloride (MsCl) and
pyridine gave the corresponding 3'-0- mesyl derivative 34. The structure of 34 (Scheme

X) was confirmed by the appearance of singlet at 6 2.95 in the

'H-NMR

spectrum for the

methyl protons of the CH3 SO 2 group.
Treatment of 34 with sodium benzoate and NN-dimethylformamide (DMF) gave
0 2,3'-anhydro-2',5'-di-0-trityluridine 35 in 43 % yield. Abstraction of hydrogen from the
uracil base by benzoate anion and attack at the basic C2-oxygen at the 3' position in
ribose induces the displacement of the mesyl group to give the desired 0 2,3'-anhydro2',5'-di-0-trityluridne 35.
Removal of the trityl protecting group from 35 was achieved with anhydrous HCl
followed by treatment of the resulting reaction mixture with ethanol (Scheme XI).
Crystallization of the crude material from methanol gave fully-deprotected 02,3'anhydro-l-(P-D-xylofyranosyl)uracil 36 (85%) as a highly polar compound in various
TLC systems.36
Regioselective protection of the 5'-OH group was accomplished by treatment of
36 with tert-butyldimethylsilyl chloride (TBDMSiC1) in pyridine.f'3 8 The 5'-O-silylated
analog 37 was obtained in 80% yield after purification on silica gel. Crystallization from
ethanol/ethyl acetate gave fine needles, and the structure was confirmed by

iH-

and 13 C-

NMR, mass spectrometry and elemental analysis (see Experimental Section).

3.2.2

SYNTHESIS OF OXYGEN LABELED BENZOYL CHLORIDE
In order to prepare

(1g,

74.5%

7

0-labeled

benzoyl chloride (Scheme XII),

17

0-labeled

enrichment) was employed. First a solution of concentrated HCl/H 217
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0 IN

N

HN

0

a**r

TrO

OH

OHs

rO

(a) Triphenylmethyl chloride/pyridine

(c)

N

(b)

OTr

Methanesulfonyl chloride/pyridine

Sodium benzoate/DF

Scheme

X: Synthesis of O2,3'-anhydrouridine

0

0

1

0

N

arO0
----

- -- +

HO

OTr
OH

36

35

b

FN

OC
CO
_

RO

4

OH

0

h}
41a (x =

16)

41b (x= "O
41c (x = 170)

R=TIDMS

37

chloride
(a) Anhydrous HCl / Ethanol / Methanolic ammonia (b) Tert-butyldimethylsilyl
Imidazole/ DMF (c) Benzoyl chloride (170 & is0)
Scheme XI: Synthesis of 2'-O-benzoyl compounds

31

was prepared by bubbling anhydrous HCl through H 2 1 7

placed in a long pressure tube.

The content of HCl (37%) in the resulting HC/H1 7 0 solution was determined on the
basis of increased mass.

Acidic hydrolysis 4 of benzonitrile (38) with HC/H

2

17

0

gave the

7

O-labeled

benzoic acid (39c) in 70% yield. The crude benzoic acid was partitioned between CH 2 Cl 2
and aqueous NaHCO 3 in order to purify it from traces of benzonitrile and benzamide.
Acidification of the aqueous layer with HCl and extraction with CH 2 CI 2 gave pure
labeled benzoic acid (39c). The product

was

characterized by 'H-NMR,

17 o-

13

C-NMR and

mass spectrometry. The mass spectrum showed a molecular ion peak at n/z 125 [MH,+ 2
x 170] with intensity 100%, and a peak at m/z 124 with intensity 34%, and peak at m/z
123 with intensity less then 2%, confirming a high level of l7 -incorporation.
In a second step, the [ 7 0]-labeled benzoic acid (39c) was treated 1.25 equiv. of
thionyl chloride.39 The resulting mixture was refluxed for 1 h at 100 C, and excess
thionyl chloride was added to keep the solution homogeneous. The reaction mixture was
then distilled. Simple distillation removed excess thionyl chloride at ~70 *C followed by
benzoyl chloride (40c) which distilled off in one fraction. The product was colorless and
had strong benzoyl chloride odor (yield 85%).

3.2.3 REARRRAGEMENT OF 2'-O-BENZOYL COMPOUNDS
Treatment
xylofuranosyl]uracil (37)

of

1-[2,3'-anhydro-5'-O-(tert-butyldimethylsilyl)--D-

(Scheme XI) with two equivalents of

7

O-benzoyl chloride

gave 2-O-benzoyl derivative 41c. "O-Labeled was incorporated at the carbonyl oxygen
in 50% yield. The product was purified on a silica gel column, and unreacted starting
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Scheme

II. Synthesis of oxygen labeled

3

enzoyl chloride

material was recovered. The product was characterized by
spectrometry and elemental analysis.
the benzoyl group.

intensity 100% for the

1

'H-

and "C-NMR, mass

H-NMR showed characteristic chemical shifts for

zl

Mass spectrometry showed a prominent peak at
7

O-labeled

446 with

molecular ion (MH-) and a peak at m/z 445 with 77%

intensity for the MH+ ion of the remaining unlabeled material indicating 56% enrichment
with

7 0-isotope.

Stereospecific rearrangement of 2'-O-benzoyl compound 41c (with

7

O-labeled

on

the carbonyl oxygen) into the 3'-O-benzoyl compound 42c (with "7O-labeled on 3'
hydroxyl directly attached to ribosyl ring) with concomitant formation of O 2'-anhydro
ring was achieved by heating compound 41c with a Bunsen burner under argon until the
solid melted and turned brown (about 1 min). This thermolysis method gave better results
then the reported procedure of Fox, et al.36 where a sand bath at 252 *C was used for
three min. TLC analysis showed that conversion was more effective and produced

more

reliable results than by direct heating. Controlling the flame temperature, however, is
demanding and inconvenient. The product was purified on a silica gel column and was
characterized by

1H-NMR,

3C-NMR,

example, the mass spectrum of 42c

mass spectrometry and elemental analysis. For

["O]

showed a +1 shift for the molecular ion relative

to 42a indicating the incorporation of one oxygen-17 atom. The

7

O-enrichment

for 42c

7
was calculated to be 55% based on the relative intensities of the MH+[ O] and the

42b
MH+[ 160] peaks for the corresponding isotopes. Analogously the mass spectrum of
[180] showed a +2 shift of the molecular ion relative to unlabeled analog 42a indicating
the incorporation of one oxygen-18 atom.
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3.3 SYNTHESIS OF 2'-AZIDO- 2'-DEOXYNUCLEOTIDES
Deprotection of the 0 2 ,2'-anhydro compounds 42 was first attempted on a small
scale with unlabeled analogue in order to find the best conditions for the removal of the

5'-O-silyl protecting group and the 3'-O-benzoyl group in the presence of the basesensitive

2,2'-anhydro bridge. Two approaches were investigated. In the first approach,

removal of the 5'-O-silyl protecting group with NH 4F/MeOH 4 0 was followed by removal
of the 3'-benzoyl group with NH 3/MeOH. TLC showed polar, lower moving compounds
in low yields. In a second approach, benzoyl protection was removed by first adding
NH 3/MeOH and stirring the compound for one hour. The 5'-O-silyl protecting group was
then removed by adding NH4F/MeOH.40 TLC indicated formation of a more polar
product as well as stability of

2

,2'-anhydro bridge.

Labeled 5'-O-TBDMS-2'- 1 7 O-benzoyl-0 2,2'-anhydrouridine (42c) was dissolved in
MeOH/NH 3 and stirred for two hours. The reaction mixture was evaporated, and the
residue was treated with excess NH 4 F in MeOH and stirred at room temperature
overnight. Purification by Reverse Phase-HPLC gave product 43c as white crystals in
65% yield. The 'H-NMR and

3

C-NMR gave identical chemical shifts for compound 43c

41
as those reported in the literature for the unlabeled analog 43a. The mass spectrum,

using the APCI technique, showed a peak at tn/z 227 with intensity 100% for MH+['60]
and a peak at tn/z 228 with intensity 98% for MH[

17

O] proving that

7

O-enric

ent at

~50% level had occurred.
Several attempts were made to synthesize 3'[

17

0]-labeled

42
First, the Moffatt procedure for the ring opening of 02,2'-a

2'-azido-2'-deoxyuridine.

ydrouridine 43a with azide

Treatment of 43a with lithium azide and

anion was tested on unlabeled compound.
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hexamethylphosphoramide (HMPA) followed by purification on silica gel and Dowex as
described by Moffat, et al.4 1 gave desired 44a in ~20% yield. Cleavage of glycosylic
linkage with the formation of uracil had occurred. Other attempts to improve the yield for
the conversion of 43a into the 2'-azido-2'-deoxyuridine failed repeatedly giving poorer
results than the 43% yield reported in the literature.4

In 1994 Kirschenbenter, et al.43 reported an improved synthesis of the 2'-azido-2'deoxyuridine employing generated in situ lithium azide. Treatment of 43a with LiF,
N,N,N,N-tetramethylethylenediamine

(TMEDA)

and azidotrimethylsilane

(Me 3 SiN 3)

reagent gave 44a in higher yield (83%) than the Moffatt procedure. A second approach

employed LiN which was complexed with 18-crown-6. While both sets of conditions
gave 2'-azido-2'-deoxyuridine in higher yield (~ 60%), difficulties in purification of the
final product from the 18-crown-6 ether was experienced in the second approach.
The 3'[ 17 0]-labeled 0 2,2'-anhydrouridine 43c was added to LiN 3 generated in situ
from LiF and Me 3SiN 3 . The reaction mixture was worked up with methanol and ethyl
acetate. After purification on silica gel and RP-HPLC, the product 44c was obtained in 27
%

yield (Scheme XIII). Proton NMR of 44c showed the identical chemical shift as

reported previously in the literature for the unlabeled analog. 42 ,43 Mass spectrometry
confirmed the presence of isotopic labeling. MS using APCI technique showed a
molecular ion peak at rn/z 271 with 100% intensity for MH+[ O] with respect to the peak
at m/z 270 for MH+[160] isotope with 98% intensity, confirming 50% enrichment of
oxygen at 3'-hydroxyl group.
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3.

PREPARATION

OF

2'-AZIDO-2'-DEOXY-3'-" 7 -URIDINE

5'-

DIPHOSPHATE
The phosphorylation of the

5'-OH

group of 2'-azido-2'-deoxyuridine was first

attempted using the method developed by Yoshikawa et al.44 This method is composed of
the introduction of a monophosphate function at the 5'-hydroxyl followed by a coupling
of the resulting 5'-monophosphate with a molecule of inorganic phosphate.28 Thus,
treatment of unlabeled 2'-azido-2'-deoxyuridine (44a) with freshly-distilled phosphorus
oxychloride and triethyl phosphate gave the corresponding 5'-monophosphate 44a which
was purified on Sephadex ion exchange resin. Crude 5'-monophosphate was purified
from excess phosphate by treatment with BaBr 2 to give 5'-monophosphate in low yield
(15%).
In order to synthesize 2'-azido-2'-deoxyuridine 5'-diphosphate compounds 46,
attention was turned to the Poulter method 45 which consists of selective 5'-O-tosylation
followed by displacement of the tosylate with inorganic pyrophosphate anion. Tosylation
of the 5'-hydroxyl function of unlabeled 2'-azido-2'-deoxyuridine 44a followed by
displacement of the 5'-O-tosylate from the resulting 45a by tris(tetra-n-butylammonium)
hydrogen pyrophosphate gave the diphosphorylated product 46a in moderate yield
(52%).

Treatment of 3'["0]-labeled 2'-azido-2'-deoxyuridine (44c) (16 mg) with 1.5
equivalents of tosyl chloride in pyridine gave a mixture of 5'-O-monotosyl product 45c
along with small quantities of the corresponding 3',5'-di-0-tosyluridine byproduct. The
5'-monotosylated compound 45c was separated from ditosylated compound on a silica gel
column. The product 45c was obtained in 63% yield and was characterized by 1H- and
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"3C-NMR and mass spectrometry. Mass spectrometry showed
based on the

170/160

50% of '7

-enrichment

isotope distribution.

In order to synthesize the final compound, 3'[

7 O]-labeled

2'-azido-2'-deoxyuridine

5'-diphosphate (46c) (Scheme XIV), tosylate 45c was treated with 1.5 equivalents of
tris(tetra-n-butylammonium)

hydrogen pyrophosphate in acetonitrile for 24 hour at

ambient temperature. The reaction mixture was evaporated to remove acetonitrile, and
the crude 46c was diluted with water and purified on a Sephadex ion exchange column
using triethylammonium bicarbonate as a gradient eluant. Proton NMR showed the
presence of triethylammonium salt in the product. The product was converted to its
sodium salt by passing it through a Dowex (Na*) column that was prepared fromn Dowex
(H+).

31
The product obtained, diphosphate 46c, was characterized by 'H-NMR and P-

NMR. Proton NMR showed no peaks for the TEA salt. Phosphorus-31 NMR showed that
compound 46c still contained 70% inorganic pyrophosphate as impurity.
The final purification of compound 46c was achieved on RP-HPLC with a semipreparative column (Supelcosil LC-18T). Elution with 3% H 2 0/CH 3CN gave the
labeled diphosphate 46c (4 mg, 22%) with a retention time of 5-6
compound was characterized by 'H-NMR and

3

'P-NMR.

minutes.

'"7-

The

Phosphorus-31 NMR showed

that the compound contained 50% of the inorganic pyrophosphate as an impurity and also
consist of two doublets of doublets at 6 -10.17 and 6- 9.26 for phosphorus u and
coupling constant of Jpp

p with

a

= 21.2 Hz diagnostic for diphosphate 46c.

Biological studies with the 3'[

7

0]-2'-azido-2'-deoxyuridine

5'-diphosphate 46c

are now being performed in Professor Stubbe's laboratory at the Massachusetts Institute
of Technology. Enzymatic studies with ribonucleoside diphosphate reductase (RDPR)
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0

involve high-field EPR experiments and site-directed mutagenated enzyme in order to
detect and fully characterize the elusive nitrogen-centered radical which is generated

during inhibition of the RDPR with 2'-azido-2'-deoxyuridine 5'-diphosphates.

4. EXPERI

ENTAL SECTION

4.1 GENERAL PROCEDURE
Melting points were determined with a capillary apparatus and are uncorrected.
Ultraviolet spectra were measured in methanol, absolute ethanol, 50% ethanol and water
using a Shimadzu UV-2101 PC scanning spectrometer. 'H-(400 MHz), "C-(100 MHz)
and 3 'P-(1 61.7 MHz) NMR spectra were recorded on a Bruker NMR spectrometer with
solutions in CDCl3 , unless otherwise specified. Mass spectra were obtained by chemical
ionization using a Finnigan navigator LC/MS with methanol as the solvent. Evaporations
were effected with a Btchi rotary evaporator under water aspirator or mechanical oil
pump at

<

35

'C.

Preparative Reverse-Phase (RP)-HPLC was performed on a Supelcosil

LC-18S column utilizing a Perkin-Elmer LC 200 binary pump system (gradient solvent
systems are noted). Elemental analyses were determined by Galbraith Laboratories,
Knoxville, TN. Merck kiselgel 60-F 254 sheets were used for TLC, and products were
detected under 254 nm light. Merck Kieselgel 60 (230-400 mesh) was used for column
chromatography. Unless otherwise specified, solvents used for column chromatography
and TLC were as follows: (Si) EtOAc; (S2) SSE [the upper phase of EtOAc/i-PrOH/H 2 0
(4:1:2)]; (S3) EtOAc/SSE (90:10); (S4) EtOAc/SSE (75:25); (S5) DSSE (30% MeOH in
SSE); (S6) CHCl/IMeOH (95:5)

(S7) i-PrOH/NH 4 OH/H2o (3:1:1). Reagent grade
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chemicals were used, and solvents were dried by reflux over and distillation from calcium
hydride under argon. Sonication was performed with a Branson 5200 ultrasonic bath. Ion

exchange chromatography was performed with Sephadex-DEAE A-25, ( 4 0 - 1 2 0 p) and
Dowex-50w-hydrogen foam, 2% cross linking, 100-200 mesh ion exchange resin.

4.2 SYNTHESIS

2',5'-Di-O-trityluridine (33)
Uridine (32) (11 g, 45 mmol), dissolved in anhydrous pyridine (95 mL), was
treated with three equivalents of triphenylmethyl chloride (36 g, 129 mmol) and allowed
to remain at room temperature overnight. The resulting red solution was heated at 110
'C for four hours after which it was cooled, poured into water, and stirred. After
decantation, the gummy solid was again treated with water, stirred and the water
decanted. This process was repeated several times after which the residue was dissolved
in acetone and concentrated to dryness. The resulting viscous liquid was treated with 500
mL of hot water, stirred, and the water decanted. This process was repeated twice. The
residue was dissolved in methylene chloride and dried over anhydrous sodium sulphate.
After filtration, the solution was concentrated and treated with a minimum amount of hot

benzene to give a homogeneous solution. Diethyl ether was added to the point of faint
opalescence. After cooling (and scratching), a creamy solid precipitated that was filtered
to give 33 (32g, 45%): mp 224-225 C (lit. 4 6 mp 223-224 "C); UV max 264

nm; 'H

MR

,

min 245

2.30 (br s, 1, OH3'), 2.80 (d, J 3_2 =4.6 Hz, 1, H3') 3.12 (br s, 2, H5',5"),

3.98 (br s, 1, H4'), 4.51 (t, J21 = 4.7 Hz, 1, H2), 5.11 (d, J, 2 = 6.1 Hz, 1, H1'), 6.36 (d,
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Js-6 = 7.4 Hz, 1, H5), 7.00-7.60 (m, 15, Haron), 770 (d, J6- 5 =8.0

z, 1, HO), 8.50 (s, 1,

NH).

3'-0-Methanesulfonyl-2'-5'-di-O-trityluridine (34)
Methanesulfonyl chloride (1.1 mL) was added dropwise to a cooled solution of 33
(8.8 g, 12 minol) in anhydrous pyridine (100 mL), and the reaction mixture was stored at

-5

"C for 16 h. A crystalline product was formed during this time. The reaction mixture

was treated with ethanol (2 mL) and allowed to stand for 2 h more. After concentration in
vacuo to a red syrup, the residue was treated with ethanol (200 mL) whereupon a heavy
white precipitate formed. After filtration and trituration of the precipitate with ethanol, a
solid was obtained (7.3 g, 75%) which was washed repeatedly with ethanol and diethyl
ether and was dried under vacuum. This crude product was recrystallized from ethanol to
afford pure 34: mp 224-226 "C (lit.36 mp 225-226 "C); UV max 259 nm, min 242 nin; 'H
NMR 6 2.95 (s, 3, Me), 3.25 ("dd", J,-= 10.8 Hz, 2, H5',5"), 4.25 (d, J-

H3'), 4.42 (br s 1, H4'), 4.66 (t, J = 7.6 Hz, 1, H2'), 5.14 (d, J5 _6

=

=

5.0 Hz, 1,

8.1 Hz, 1, H5), 6.99 (d,

Jl'2 = 7.8 Hz, 1, H1'), 6.96 (d, J 6-5= 7.4 Hz, 1, H6), 7.00-7.80 (m, 15, Harom), 8.80 (s, 1,
NH).

1-(2, 3'-Anhydro -2', 5'-di-O-trityl-P-D-xylofuranosyl)uracil (35)
Compound 34 (7.0 g, 8.7 mnol) was added to a suspension of sodium benzoate
(14 g) in DMF (280 mL) and heated at 130-140 C (internal temperature) for 18 h. The
cooled mixture was treated with 1 L of water and stirred for 2 h. The precipitate was
separated and washed well with water. After filtration, the precipitate was triturated with
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ethanol (100 mL) whereupon a white granular precipitate slowly formed. After 2 h of
stirring, the precipitate was filtered from the amber colored solution. The precipitate was
directly chromatographed on a silica gel column. Gradient elution (80% EtOAc/hexane

9 EtOAc

5%

MeOH/EtOAc) and evaporation of the appropriate fractions (Rf in Si

0.8) gave 35 (2.6 g, 43%); mp 237-238 *C (lit.36 237 "C); UV max 248, 269 (shoulder)
nm, min 239
4-

; 'H NMR 6 3.29 (dd, J 5 " = 9.7 Hz,

&5'4

= 3.2 Hz, 1, H5"), 3.34 (dd, J3,

4.2 Hz, H5'), 4.03 (q, J 4 r'= 6.8 Hz, 1, H4'), 4.41 ("s", 1, H3'), 4.53 ("dt", J 2 3 = 2.1

Hz, 1, H2'), 4.59 (s, 1, H1'), 5.76 (d, J 5 -6 = 7.4 Hz, 1, H5), 6.28 (d, J 6 -5 = 7.4 Hz, 1, H6),
7.00-7.50 (m, 15, Harom).

1-(2, 3'-Anhydro-p-D-xylofuranosyl)uracil (36)
Compound 35 (2.2g, 3.0 mmol) was placed in ethanol (50 mL) which had been
saturated with anhydrous hydrogen chloride (0 'C for 10 minutes), and kept ~70 C for
10 miniuets.

The solution was concentrated in vacuo to a syrup and repeatedly

evaporated with benzene. Absolute ethanol (10 mL) was added to the syrup and cooled to
0 *C. The resulting solution was neutralized to about pH 5 with methanolic ammonia
whereupon crystallization took place. Recrystallization from 95% methanol gave pure 36
(0.6 g, 85%); mp. 227-228 *C (lit.36 mp 225-227); UV max 231 nm, min 215 nm; '
NMR (D2O) 6 3.61 (m, 2, H5', 5"), 4.45 (s, 1, H4'), 4.70 (br s, 1, H3'), 4.97 (s, 1, H2'),
5.55 (br s, 1, H1'), 5.91 (d, Js-6 = 7.3 Hz, 1, H5), 7.55 (d, 6.-= 7.4 Hz, 1, H6).
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1-[2,

ydro-5'- -(tert-buty dimethylsilyI)-p- -xylofuranosyl uracil (37)

3-

To a suspension of 1-(2,3'-anhydro--D-xylofuranosyl)uracil (36) (1.13 g, 5
mmol) in anhydrous DMF (30 mL) were added imidazole (0.725 g, 12.5 mmol) and tert-

butyldimethylsilyl chloride (0.903 g, 6.0 mmol).

The reaction mixture was stirred

overnight under argon at ambient temperature. Volatiles were evaporated under vacuum,

and the residue was directly chromatographed on a silica gel column. Gradient elution

[EtOAc

-

50% S2/EtOAc

-

MeOH/S2 /EtOAc (2:49:49)] and evaporation of the

appropriate fractions (Rf 0.71 in S3; compound 36 had Rf 0.1) gave 37 (1.36 g, 80%).
Crystallization from EtOH/EtOAc gave sharp needles: mp 246-247 *C; UV max 231 nm
(c 9800), min 216 nm

(

6900); IH NMR (DMSO-d 6 ) 6 0.02 (s, 6, 2 x Me), 0.85 (s, 9, t-

Bu), 3.71 (dd, J5"-5'= 11.0 Hz, J5-.4 = 6.4 Hz, 1, H5"), 3.81 (dd, Je_
4 = 6.0 Hz, 1, H5'),
4.41 ("dt", J 4 -5%
5" = 6.2 Hz, J4-= 2.5 Hz, 1, H4'), 4.74 (br s, 1, H3'), 4.92 (br s, 1, H2'),
5.64 (s, 1, HP'), 5.80 (d, J 5 = 7.4 Hz, 1, H5), 6.45 (br s, 1, OH2'), 7.68(d, 1, H6);

1C

NMR (DMSO-d 6 ) 6 - 5.00 (2 x Me), 18.27 (t-Bu), 25.99 (t-Bu), 61.37 (C5'), 69.73 (C3'),
79.47 (C2'), 83.58 (C4'), 89.64 (Cl'), 108.19 (C5), 141.33 (C6), 153.67 (C2), 170.59 (
C4);

MS (CI)

n/?

341 (100, MH+),

283 (30, M*- t-Bu); HRMS (CI) calcd. for

C15 H 4 N25Si + H. 341.1532. Found 341.1538. Anal. Calcd. for C1 5H24N205Si (340.45):

C, 52.92; H, 7.11; N, 8.23. Found: C, 52.43; H, 7.26; N, 8.11.

Preparation of Concentrated HCI in
The Ox ygen-18-labeled

1

8

O-Labeled H20

ater (1.05 g, 52.5 mmol; 97.4 atom % 180 from Isotec,

Inc.) was placed in long pressure tube (Ace glass) and was cooled in an ice bath.

45

Anhydrous hydrogen chloride was bubbled in for 3 mm, and the content of HCI (37%)
was calculated on the basis of increased mass.

Preparation of

8
1

8
0-Labeled Benzoic Acid from Beuzonitrile and HC1/H21 0

(39b)
Benzonitrile (38) (1.78 ml, 1.8 g, 17.5 mmol) was suspended in concentrated
HCl/H 2' 80 (prepared as above) in a long pressure tube, and the reaction mixture was
heated for 20 h at 100 *C with vigorous stirring. During that time the whole reaction
mixture solidified. The reaction mixture was then partitioned between cold methylene
chloride and ice-cold, saturated aqueous NaHCO 3 solution. The methylene chloride layer
was then quickly extracted again with NaHCO 3 solution. The aqueous extracts were
combined and water layer was extracted back with CH 2 Cl 2 to remove traces of
benzonitrile and benzamides. Fresh methylene chloride was then added to the water layer,
and the

mixture

was acidified to pH ~3.

The aqueous layer was separated, and the

CH 2Cl 2 layer was extracted with brine. The methylene chloride layer was then dried
(anhydrous Na 2SO4) and evaporated to give 39b (1.55 g, 70%) as a white solid. 'H NMR
6 7.49 (t, J = 7.4 Hz, 2, H), 7.65 (t, J = 7.4 Hz, 1,H), 8.15 (d, J= 7.0 Hz, 2,H), 13.00 (s,

1, COOH);

3

C NMR 6 128.99 (C3), 129.81 (Cl), 130.72 (C2), 134.34 (C4) 173.05

(COOH); MS (CI)

/z 127 (100, MH+ [2 x 180]), 126 (60) 125 (20), 124 (19), 107 (65,

PhC"5O+), 105 (2, PhCO ) and no peaks at

m/z

benzoic acid.
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122 and 123 were observed for unlabeled

Preparation of Concentrated HCI in "7 O-Labeled H20
Oxygen-17 labeled water (1 .08 g, 57.7 rnol; 74.5 atom %

170

from Isotec, Inc.)

was placed in a long pressure tube (Ace glass) and was cooled in an ice bath. Anhydrous

hydrogen chloride was bubbled in for 3 min, and the content of HCl (35.2%) was
calculated on the basis of increased mass.

Preparation of

7

- Labeled Benzoic Acid from Benzonitrile and HC1H 217 0

(39c)
Treatment of benzonitrile (38) (2.08 g, 2.06 ml, 20.2 mmol) with HCl/H 21 0
(prepared as above) was effected as described for 39b and afforded gave

benzoic acid 39c (1.54 g, 62% ). MS (CI)

i/z

7

O-labeled

125 (100, MH+ [2 x "0]), 124 (34,

MH+["O 6 ]), 123 (21, MH [2 x 16])

Preparation of 1 8 0-Labeled Benzo yl Chloride (40b)
' 8 0-Labeled benzoic acid (39b) (0.88 g, 6.98 mmol) was placed in a 25 mL
round-bottomed flask, and thionyl chloride (0.65 mL, 1.05 g, 8.8

ol) was added. The

reaction mixture was gently heated for 1 h at 100 'C (an additional 1 mL of thionyl
chloride was added after 20 min. to minimize the effect of loss of thionyl chloride during
heating and to keep the solution homogeneous). The reaction mixture was cooled after
one hour and distilled. Simple distillation at atmosphere pressure removed excess SOC12
(~70 "C). Vacuum was then applied, and the temperature was increased to ~130 "C to
distill most of the liquid in one fraction to give 40b (0.85 g, 85%). The distilled liquid
was colorless and had strong odor of benzoyl chloride.
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Preparation of "O-Labeled Benzoyl Chloride (40c)
Treatment of the

7

1

0-labeled

benzoic acid (39c) (1.4 g, 11.29 mmol) with thionyl

chloride (1.67 g, 14.11 mmol) as described for 40b gave ["7O] benzoyl chloride (40c) (1.3
g, 80%).

1-[2,3'-Anhydro-2'-O-benzoy-5'--(tert-butyldimethylsilyl)-p3-D-xylofuranosyl
uracil (41a)
To a solution of 37 (20 mg, 0.05 mmol) in anhydrous pyridine (1 mL) was added
benzoyl chloride (0.05 mL) and stirring was continued overnight at ambient temperature
and then for 2 h at 40 *C. Volatiles were removed in vacuo, and the residue was coevaporated with toluene. The crude product was chromatographed on a silica gel column.
Gradient

elution

[EtOAc/hexane

EtOAc

(90:10)-

4

5%

S2/EtOAc

-

MeOH/S2/EtOAc (2:10:88)] and evaporation of the appropriate fractions (Rf 0.64 in S3;
compound 37 had Rf 0.12) gave compound 41a (10 mg, 50%) as a white solid: mp 238240 *C; UV max 233 nm (s 26 100), min 213 nm

(

Me), 0.85 (s, 9, t-Bu), 3.89 (dd, J "-5,= 10.7 Hz, J5"
6.0 Hz, 1, H5'), 4.70 ("dt", J4',5

12 000); 1H NMR 6 0.02 (s, 6, 2 x
4

= 7.3 Hz, 1, H5"), 3.93 (dd, J' 4 ' =

= 7.4 Hz, J4'3= 2.5 Hz, 1, H4'), 5.22 (br s, 1, H3'), 5.55

6 = 7.3 Hz, 1, H5), 7.21 (d, 1, H6) 7.52 (t, J=
(br s, 1, H1'), 5.70 (br s, 1, H2'), 6.13 (d, J$_

7.9 Hz, 2, Harom), 7.70 (t, J

7.4 Hz, 1, Harom), 8.06 (d, J= 7.1 Hz, 2, Harom);

1C

NMR 6 -

0.50 (2 x Me), 18.76 (t-Bu), 26.24 (t-Bu), 61.09 (C5'), 72.63 (C2'), 77.61 (C3'), 85.22
(C4); MS (CI) m/Z 445
(C4'), 88.82 (C1'), 110.53 (C5), 139.81(C6), 153.51 (C2), 171.35
H, 6.35; N, 6.30. Found:
(100, MH+). Anal. Cald for C22H 28N 20 6 Si (444.56): C, 59.44;
C, 59.03; H, 6.57; N, 6.30.
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1-[2,3'- nydro-2'-1$0-benzoyl-5'-

-(tert-butyldimethylsilyl)--

-

xylofuranosylluracil (41b)
Treatment of 37 (200 mg, 0.59 mmol) with

0-labeled

15

benzoyl chloride (40b)

(0.14 mL) as described for 41a gave compound 41b (180 mg, 68%) with identical
physical and spectroscopic properties except for the mass spectrum: MS (CI) m/z 447
(100, MH[1s

]), 445 (16, MH["0]).

1-[2,3 '-Anhydro-2 '- 0-benzoyl-5'-O-(tert-butyldimethylsilyl)-P-Dxylofuranosyl]uracil (41c)

Treatment of 37 (1.15 g, 3.3 mmol) with 17 O-labeled benzoyl chloride (40c) (0.5
ml) as described for 41a gave compound 41c (0.45 g, 30%) with identical physical and
spectroscopic properties except for the mass spectrum. MS (CI) m/z 446 (100, 446
MH["O]), 445 (77, MH[160]).

1-[2,2'-Anhydro-3'-O-benzoyl-5'-O-(tert-butyldimetylsiyl)-p-Darabinofuranosyl]uracil (42a)
Compound 41a (100 mg, 0.22 mmol) was placed in a 25 mL round bottomed
flask and heated directly by Bunsen burner under argon for 1 mi

until the solid melted

and turned brown. After cooling, the product was directly chromatographed on a silica
gel column. Gradient elution [EtOAc

-

10%/S2/EtOAc

-

MeOH/S2/EtOAc(2:10:88)]

and evaporation of the appropriate fraction (Rf 0.75 in S4; and compound 41a had Rf
0.37) gave compound 42a (65 mg, 65%) as a white solid: mp 224-226 C; UV max 231
nrm (E 20 100),

in 210 nrm (F 9000); H NMR 6 0.02 (s, 6, 2 x Me), 0.90 (s, 9, t-Bu),
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3.67 (dd, J 5"-5'= 11.1 Hz, J 5"-4' = 4.4 Hz, 1, H5"), 3.81 (dd, J 5 '-4 = 5.9 Hz,

1, H5'), 4.50

("dt", J 4 -5% 5"= 4.4 Hz, J 4' 3 = 2.6 Hz, 1, H4'), 5.60 (d, J24. = 5.5 Hz, 1, H2'), 5.70 (br s, 1,
H3'), 6.08 (d, J5 -6 = 7.4 Hz, 1, H5), 6.42 (d, J- -2

=

5.7 Hz,1, H1') 7.42 (d, J 6-5 = 7.4 Hz,

1, H6) 7.50 (t, J= 7.9 Hz, 2, Harom), 7.65 (t, J= 7.4 Hz, 1, Harom), 8.05 (d, J= 7.2 Hz, 2,
Harom);

13

C NMR 6

-0.50

(2 x Me), 19.01(t-Bu) , 26.35 (t-Bu), 63.58 (C5'), 78.34 (C4'),

87.38 (C3'), 88.77 (C2'), 91.18 (Cl'), 110.59 (C5), 128.84-134.42 (Carom), 160.09 (C2),
165.84 (Cbz), 170.42 (C4); MS (CI) m/z 445 (100, MH+). Anal. Cald. for C 22H28 N 20 6 Si
N, 6.32.
(444.56): C, 59.44; H, 6.35; N, 6.30. Found: C, 59.80; H, 6.42;

1-[2,2'-Anhydr -3'-1O-be zoyl-5'-0-(tert-bu yldimethylsilyl)--arabinofuranosylUracil (42b)
for 42a gave 42b
Treatment of compound 41b (70 mg, 0.15 mmol) as described
spectroscopic properties except for the mass
(44 mg, 63%) with identical physical and
spectrum. MS (CI)

m/z 447 (100,

1-[2,2'-Anydro-3'-"

7
MH+["jO]), 445 (35, 445 MH+[ O]).

-be zoyl-5'-

-(tert-butyldi ethylsilyl)-@-D-

arabinofuranosylluracil (42c)
as described for 42a gave
Treatment of compound 41c (50 mg, 0.11 mmol)
physical and spectroscopic properties except
compound 42c (27 mg, 54%) with identical
6
7
O]), 445 (85, MH+[' O]).
for the mass spectrum. MS (Cl) /z 446 (100, MH+[1
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1-(2,2'-Anhydro-

p-D-arabinofuranosyl)uracil

Compound 42a (22

(43a)

g, 0.5 mmol) was dissolved in a saturated solution of NH 3 in

MeOH (5 mL) and was stirred at ~0 *C. After 2 h, the reaction mixture was evaporated,
and to the white residue NH 4F (28 mg, 0.75 mmol) and anhydrous MeOH (5 mL) were
added to the white residue. The resulting solution was stirred at room temperature
overnight. TLC in S5 showed compound 43a with Rf 0.

(compound 42a had Rf 0.75).

Volatiles were evaporated, and the residue was purified on RP- HPLC (elution 8%
CHCN/92% H 2 0, retention time 25 min.) to give compound 43a as off-white crystals (8
mg, 71%): mp 244-245 *C (lit.

6

mp 238-244'C); UV max 225, 251 nm (c 7000, 5850),

min 237, 212 nm (c 5200, 5200); 'H NMR (DMSO-d 6)
(t, J3- 2
2=

=

4.5 Hz, 1,

3'), 4.38 (s, 1, H4'),

3.16-3.47 (in, 2, H5',5"), 4.07

4.99 (t, J5OH. 5'/S"= 5.2 Hz, 1, OH5'), 5.20 (d, Jy.

5.6 Hz, 1, H2'), 5.85 (d, J 5.6 = 7.4 Hz, 1, H5), 5.90 (d, J3OH- Y'= 4.3 Hz, 1, 0H3'), 6.31

(d, J-2'

=

5.7 Hz,1, H1') 7.85 (d,

6-5 = 7.4 Hz, 1, H6);

3

C NMR (DMSO-d 6 ) 6

61.68(C5'), 75.77(C4'), 89.60(C3'), 90.08(C2'), 90.88(C1'), 109.46(C5), 137.73(C6),
160.66(C2), 172.07(C4); MS (CI) i/ 227 (100, MH+[160]).

1-(2,2'-Anhydro-3'-1 0--D-arabinofuranosyl)uracil (43b)
Deprotection of compound 42b (8 mg, 0.034 mmol) as described for 42a gave
compound 43b (3mg, 73%) with identical physical and spectroscopic properties except

for the mass spectrum: MS (CI) m/z 229 (100, MH+["O]), 227 (37, MH+[160]).
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1-(2,2'-Anhydro-3'-" 0-3-D-arabinofuranosyl)uracil (43c)
Deprotection of compound 42c (22 mg, .05 mmol) as described for 42a gave

compound 43c (7.4 mg, 65%) with identical physical and spectroscopic properties except
for the mass spectrum: MS (CI) m/z 228 (98, MH+[17O]), 227 (100, MH+[160]).

2'- Azido-2'-deoxyuridine (44a)
Lithium fluoride (47 mg, 1.8 mmol) was suspended in DMF (2 mL), and the
resulting suspension was heated

to

105

C with

stirring.

Then NNN

-

tetramethylethylenediamine (2 mL) was added followed by azidotrymethylsilane (0.24
mL).

After stirring for 30 min, compound 43a (0.226 g, 1.0 mnol) was added, and the

reaction was allowed to proceed for 48 h at 110 "C (oil bath temperature). The volatiles
were evaporated under vacuum, and the residue was co-evaporated three times with
methanol. The residue was dissolved in methanol (10 mL), and ethyl acetate (40 mL) was
added to precipitate most of the salts and residual starting materials. The filtered solution
was applied to a silica gel column and eluted with methanol/ethyl acetate (20/80) to give
44a (0.22 g, 83%) as a yellowish foam (0.22 g, 83%). This material was re-purified by

RP-HPLC (elution, 15% CH 3CN/85% H2 0) to yield pure 44a (0.14 g, 52%) as an offwhite foam: UV max 261 nm, min 232 nm;

'H

NMR (DMSO-d 6 ) 6 3.62 (i, 2, H5'/5"),

3.89 (s, 1, H4'), 4.04 (d, J3-2,= 5.3 Hz, 1, H3'), 4.29 ('q', J2 -1y
J5'OH. 5'/5"=

=

5.0 Hz, 1, H2'), 5.20 (t,

5.0 Hz, 1, OH5'), 5.68 (d, J5 -6 = 8.0 Hz, 1, H5), 5.87 (d, JoH.. 3'= 5.4 Hz, 1,

0H3'), 5.90 (d, J-2'= 5.4 Hz, 1, H1') 7.67 (d, J6.5= 8.0 Hz, 1, H6), 11.4 (s, 1, NH); MS
(CI) m/z 270 (100, MH[ 160]).
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2'-Azido-3'-"7-2'-deoxyuridine (44c)

Treatment of compound 43c (50 mg, 0.22 mmol) as described for 44a gave
compound 44c (27 mg, 45%) as a yellowish foam.

RP-HPLC purification gave

compound 44c as an off-white foam (16 mg, 27%) with identical physical and
spectroscopic properties except for the mass spectrum: MS (APCI) m/z 271 (100,
MH+[170]), 270 (98, MH+[16{x]).

2'-Azido-2'-deoxy-5'-O-(para-toluenesufonyl)uridine (45a)
P-toluenesulfonyl chloride (21.08 mg, 0.11 mmol) was added to a stirred solution
of compound 44a (20 mg, 0.074 mmol) in anhydrous pyridine (1
temperature.

mL) at ambient

After 14 h the reaction mixture was evaporated, and the residue was

partitioned (0.1 N HCl/H 20//CHCl 3 ). The organic layer was washed (NaHCO 3, NaCI),
dried (MgSO 4), and evaporated. TLC in S6 showed a small amount of upper

moving

3',5'-O-ditosylated compound, but the lower moving 5'-O-monotosylated 45a was the
major product. This crude material was chromatographed on a silica gel column. Gradient
elution (CHCl 3

--

5% MeOH/CHCl 3) and evaporation of the appropriate fractions (Rf for

compound 45a in S6 was 0.4 and 3',5'-O-ditosylated byproduct had R 0.6) gave

compound 45a (21 mg, 67 %): UV max 226, 262 nm; 'H NMR

4.17 (s, 2, H5'/5"), 4.32

("t",J= 11.1 Hz, 1, H4'), 4.36 (br s 1, H3') 4.40 ("d", J= 5.5 Hz, 1, H2'), 5.75 (d, J5 6 =
8.0 Hz, 1, H5), 5.88 (d, J12'= 2.8 Hz, 1, H1'), 7.41 (d, J= 7.6 Hz, 2, Harom) 7.51 (d, J6 _5 =
7.7 Hz, 1, H6) 7.82 (d, J= 7.4 Hz, 2, Harom) 9.24 (s, 1, NH); "C NMR 6 22.16 (Me),

66.32 (C5'), 67.90 (C3') 70.18 (C2'),
(C3arom) 130.65 (C2arom) 132.43 (C4arom)

81.65(C4'), 88.72 (C1'), 103.31(C5), 128.31
139.68 (C6), 145.50 (Claom) 150.51 (C2),
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163.49 (C4); MS (APCI) m/z 424 (100, MH+[160]), 425 (17.5, MH+["60]+1), 426 (8,
MH+[160]+2)

2'-Azido-2 '-deoxy-3'-1 O-5'-O-

ara-toluenesufonyl)uridine (45c)

Treatment of compound 44c (17 mg, 0.063 mmol) with tosyl chloride as
described for 45a gave compound 45c (17 mg, 63%) with identical physical and
spectroscopic properties except for the mass spectrum: MS (APCI) m/z 424 (98,

MH+[160]), 425 (100, MH+[17 0]), 426 (45, MH+[170]+1).

Preparation of tris(Tetra-n-butylammonium) hydrogen Pyrophosphate
Method A. Tetrasodium pyrophosphate (1.11g, 2.5 mmol) was dissolved in
deionised water (10 mL). The dissolved salt was applied to a column of Dowex 50W x
2-200 (He) ion exchange resin (2% cross linking, 100-200 mesh, hydrogen form) and
eluted with deionised water (~30 mL). Acidic fractions (pH ~1.5) were collected, and the
resulting solution was neutralized (pH ~7.3) by dropwise addition of a 40% (wt/wt)
solution tetra-n-butylammonium hydroxide in water. The neutralized solution was
evaporated to yield a viscous, clear syrup, which upon high vacuum drying gave a
hygroscopic white solid (2.2 g, 98%).

4H), 3.02 (t, J= 8.3 Hz, 2H);

31P

'H NMR (D 20), 0.77 (t, J= 7.3 Hz, 3H),

1.20 (in,

NMR (D2 0) -6.67 (s).

Note: Tetrasodium pyrophosphate can be substituted by disodium hydrogen
pyrophosphate to give tris(tetra-n-butylammonium) hydrogen pyrophosphate (97% yield)
with identical spectroscopic characteristics.
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Method B. A 10% solution (v/v) of disodium hydrogenpyrophosphate (3.3g,

15.0 mnol) in aqueous ammonium hydroxide (15 mL) was passed through a 2.5 cm x 7.0
cm column of Dowex 50WX2-200 ion exchange resin (2% cross linking, 100-200-mesh,
hydrogen form). The free acid was eluted with deionised water (100 mL), and the
resulting solution (pH ~1.5) was immediately neutralized to pH 7.3 with aqueous tetra-nbutylammonium hydroxide. The resulting solution (approximately 150 ml total volume)
was dried by lyophilization to yield 13.1 g (97%) of a hygroscopic white solid.

2'-Azido-2'-deoxyuridine 5'-diphosphate (46a)
Compound 45a (7 mg, 0.017 mmol) was dissolved in acetonitrile (0.2 mL) and
tris(tetra-n-butylammonium) hydrogen pyrophosphate (25 mg, 0.028 mmol), prepared as
above, was added in one portion. The reaction mixture was stirred at room temperature
for 48 h. Volatiles were evaporated, and the residue was dissolved in water and purified
on an ion exchange column (Sephadex-DEAE A-25,

4 0-120pt).

Gradient elution with

triethylammonium bicarbonate (0.05N 4 0.5N), evaporation of the appropriate fractions,
and co-evaporation with H 2 0 and MeOH (Rr for compound 46a in S7 was 0.6 and
compound 45a had Rf 0.8) gave compound 46a as the triethylammonium salt (4.2 mg,

52%): UV max 261 nm, min 227 nm; H NMR (D2 0) 6 4.09 (m 2, H5'/5"), 4.14 ("t", J
2.8 Hz, 1, H4'), 4.26 (t, J2t= 5.3 Hz, 1, H3') 4.49 (t, J2,, = 5.0 Hz, 1, H2'), 5.84 (d, J5 _31
8.1 Hz, 1, H5), 5.95 (d, Jv-2 = 5.2 Hz, 1, H1'), 7.85 (d, J6-5= 8.0 Hz, 1, H6); P NMR -

10.24 (d, J= 19.5 Hz), -9.57 (br s). 'H NMR showed a triplet (1.2 ppm) and a quartet
(3.4 ppm) for the triethylammonium counterions, and

'P

NMR showed a considerable

amount of pyrophosphate impurity (-9.50 ppm) in the product.
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2'-Azido-2'-deoxy-3'- 1"-uridine
Treatment

of

compound

5'-diphosphate (46c)
45c

(17

mg,

mmol)

0.041

with

tris(tetra-n-

butylammonium) hydrogen pyrophosphate (54 mg, 0.06 mmol) as described for 46a gave
compound 46c. Purification with ion exchange resin (Sephadex-DEAE A-25, 40-1.20p)
and co-evaporation with H 20 and MeOH gave 46c (8 mg, 44%). This compound was
dissolved in water and converted to the sodium salt by passing a solution through a
DOWEX (Nat) column [prepared from DOWEX-50W (He), 2%-cross linking, 100-200
mesh]. Final purification by RP-HPLC (gradient elution, 3% H2 0/CH 3CN, RT-5.6 min.,
semi-prep column, supelcosil LC-18T) gave 46c (4 mg, 22%) with 50% pyrophosphate as

impurity: 1H NMR (D2 0) 6 4.09 (m 2, H5'5"), 4.14 ("t", J
= 5.3Hz, 1, H3') 4.49 (t,
=

J2

=

2.8 Hz 1, H4'), 4.26 (t, JY-

= 5.0 Hz, 1, H2'), 5.84 (d, J5 -6 =8.1 Hz, 1, H5), 5.95 (d, j1

5.2 Hz, 1, H1') 7.85 (d, J6_5 = 8.0 Hz, 1, H6); 31P NMR -10.17 (d, J = 21.1Hz, Pe), -

9.26 (d,

J= 21.1

Hz, Pp).
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CONCLUSION

Ribonucleotide reductases (RNRs) are enzymes that execute 2'-deoxygenation of
ribonucleoside 5'-di and tri-phosphates in unique de novo biosynthetic pathways to DNA

monomers. In 1976, it was reported that pyrimidine 2'-azido-2'-deoxynucleotide 5'diphosphates were potent inactivators of ribonucleoside diphosphate reductase (RDPR).
Inactivation of RDPR by 2'-azido 2'-deoxynucleosides was accompanied by appearance
of a new EPR signal for a nitrogen-centered radical with concomitant decay of the peaks
of tyrosyl radical. This nitrogen-centered radical has been characterized by EPR
spectroscopy and shown to be composed of a 1:1:1 anisotropic triplet arising from
interaction with a single nitrogen and a second hyperfine interaction possibly derived
from a proton. The structure of this elusive nitrogen radical has been studied extensively
and shown to be derived from the azide moiety. EPR and site-directed mutagenesis
studies with the model compounds have led to the conclusion that the nitrogen-centered
radical must have the structure XN'Seys22sR1 in which X is an oxygen or carbon atom
(presumably 3') having no hydrogen attached or with a single hydrogen attached.
The goal of this study was to synthesize 3'[

17 0]-2'-azido-2'-deoxyuridine

'-

diphosphate. Such a labeled analogue should perturb the EPR spectrum of nitrogen
centered radical in a predictable fashion, and the hyperfine interaction between the free
electron and the

17

nucleus should allow a choice between the recently proposed

structures of nitrogen-centered radical by Vander Donk, et al (J Am. Chem. Soc. 1995,
117,8908). In addition, this stereoselective 17 0-labeling methodology could be employed
as a general procedure for the synthesis of 3'["7O and I O] labeled pyrimidine
nucleosides.
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The labeled 2'-azido-2'-deoxynucleotides were prepared by thermolysis of01 ,anhydrouridine

to

give

the

more

stable

O 2,2'-anhydrouridine

derivatives

concomitant rearrangement of the 2'-O-benzoyl[ 1 7 0] group into the 3'-[

1

with

O]-benzoyl

intermediate. Deprotection and ring opening with LiF/Me 3SiN 3 gave the 3'[ 17 O]-2'-azido2'-deoxyuridine. Tosylation (05') and displacement of the 5'-tosylate by treatment with
tris(tetra-n-butylammonium)

hydrogen

pyrophosphate

gave

3'[

17 0]-2'-azido-2'-

deoxyuridine 5'-diphosphate. All intermediates and products were characterized by 'HNMR, 13 C-NMR,

3

P-NMR, and isotopic enhancement was confirmed by using mass

spectrometry.
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